Cargando…
The HIV-Brazil Cohort Study: Design, Methods and Participant Characteristics
BACKGROUND: The HIV-Brazil Cohort Study was established to analyze the effectiveness of combination antiretroviral therapy (cART) and the impact of this treatment on morbidity, quality of life (QOL) and mortality. The study design, patients’ profiles and characteristics of cART initiation between 20...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006775/ https://www.ncbi.nlm.nih.gov/pubmed/24789106 http://dx.doi.org/10.1371/journal.pone.0095673 |
_version_ | 1782314259410059264 |
---|---|
author | Grangeiro, Alexandre Escuder, Maria Mercedes Cassanote, Alex Jones Flores Souza, Rosa Alencar Kalichman, Artur O. Veloso, Valdiléa Ikeda, Maria Letícia Rodrigues Barcellos, Nêmora Tregnago Brites, Carlos Tupinanbás, Unai Lucena, Noaldo O. da Silva, Carlos Lima Lacerda, Heloisa Ramos Grinsztejn, Beatriz Castilho, Euclides Ayres |
author_facet | Grangeiro, Alexandre Escuder, Maria Mercedes Cassanote, Alex Jones Flores Souza, Rosa Alencar Kalichman, Artur O. Veloso, Valdiléa Ikeda, Maria Letícia Rodrigues Barcellos, Nêmora Tregnago Brites, Carlos Tupinanbás, Unai Lucena, Noaldo O. da Silva, Carlos Lima Lacerda, Heloisa Ramos Grinsztejn, Beatriz Castilho, Euclides Ayres |
author_sort | Grangeiro, Alexandre |
collection | PubMed |
description | BACKGROUND: The HIV-Brazil Cohort Study was established to analyze the effectiveness of combination antiretroviral therapy (cART) and the impact of this treatment on morbidity, quality of life (QOL) and mortality. The study design, patients’ profiles and characteristics of cART initiation between 2003 and 2010 were described. METHODOLOGY/PRINCIPAL FINDINGS: Since 2003, the HIV-Brazil Cohort has been following HIV-infected adults receiving cART at 26 public health care facilities, using routine clinical care data and self-reported QOL questionnaires. When not otherwise available, data are obtained from national information systems. The main outcomes of interest are diseases related or unrelated to HIV; suppression of viral replication; adverse events; virological, clinical and immunological failures; changes in the cART; and mortality. For the 5,061 patients who started cART between 2003 and 2010, the median follow-up time was 4.1 years (IQR 2.2–5.9 years) with an 83.4% retention rate. Patient profiles were characterized by a predominance of men (male/female ratio 1.7∶1), with a mean age of 36.9 years (SD 9.9 years); 55.2% had been infected with HIV via heterosexual contact. The majority of patients (53.4%) initiated cART with a CD4(+) T-cell count ≤200 cells/mm(3). The medications most often used in the various treatment regimens were efavirenz (59.7%) and lopinavir/ritonavir (18.2%). The proportion of individuals achieving viral suppression within the first 12 months of cART use was 77.4% (95% CI 76.1–78.6). Nearly half (45.4%) of the patients presented HIV-related clinical manifestations after starting cART, and the AIDS mortality rate was 13.9 per 1,000 person-years. CONCLUSIONS/SIGNIFICANCE: Results from cART use in the daily practice of health services remain relatively unknown in low- and middle-income countries, and studies with the characteristics of the HIV-Brazil Cohort contribute to minimizing these shortcomings, given its scope and patient profile, which is similar to that of the AIDS epidemic in the country. |
format | Online Article Text |
id | pubmed-4006775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-40067752014-05-09 The HIV-Brazil Cohort Study: Design, Methods and Participant Characteristics Grangeiro, Alexandre Escuder, Maria Mercedes Cassanote, Alex Jones Flores Souza, Rosa Alencar Kalichman, Artur O. Veloso, Valdiléa Ikeda, Maria Letícia Rodrigues Barcellos, Nêmora Tregnago Brites, Carlos Tupinanbás, Unai Lucena, Noaldo O. da Silva, Carlos Lima Lacerda, Heloisa Ramos Grinsztejn, Beatriz Castilho, Euclides Ayres PLoS One Research Article BACKGROUND: The HIV-Brazil Cohort Study was established to analyze the effectiveness of combination antiretroviral therapy (cART) and the impact of this treatment on morbidity, quality of life (QOL) and mortality. The study design, patients’ profiles and characteristics of cART initiation between 2003 and 2010 were described. METHODOLOGY/PRINCIPAL FINDINGS: Since 2003, the HIV-Brazil Cohort has been following HIV-infected adults receiving cART at 26 public health care facilities, using routine clinical care data and self-reported QOL questionnaires. When not otherwise available, data are obtained from national information systems. The main outcomes of interest are diseases related or unrelated to HIV; suppression of viral replication; adverse events; virological, clinical and immunological failures; changes in the cART; and mortality. For the 5,061 patients who started cART between 2003 and 2010, the median follow-up time was 4.1 years (IQR 2.2–5.9 years) with an 83.4% retention rate. Patient profiles were characterized by a predominance of men (male/female ratio 1.7∶1), with a mean age of 36.9 years (SD 9.9 years); 55.2% had been infected with HIV via heterosexual contact. The majority of patients (53.4%) initiated cART with a CD4(+) T-cell count ≤200 cells/mm(3). The medications most often used in the various treatment regimens were efavirenz (59.7%) and lopinavir/ritonavir (18.2%). The proportion of individuals achieving viral suppression within the first 12 months of cART use was 77.4% (95% CI 76.1–78.6). Nearly half (45.4%) of the patients presented HIV-related clinical manifestations after starting cART, and the AIDS mortality rate was 13.9 per 1,000 person-years. CONCLUSIONS/SIGNIFICANCE: Results from cART use in the daily practice of health services remain relatively unknown in low- and middle-income countries, and studies with the characteristics of the HIV-Brazil Cohort contribute to minimizing these shortcomings, given its scope and patient profile, which is similar to that of the AIDS epidemic in the country. Public Library of Science 2014-05-01 /pmc/articles/PMC4006775/ /pubmed/24789106 http://dx.doi.org/10.1371/journal.pone.0095673 Text en © 2014 Grangeiro et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Grangeiro, Alexandre Escuder, Maria Mercedes Cassanote, Alex Jones Flores Souza, Rosa Alencar Kalichman, Artur O. Veloso, Valdiléa Ikeda, Maria Letícia Rodrigues Barcellos, Nêmora Tregnago Brites, Carlos Tupinanbás, Unai Lucena, Noaldo O. da Silva, Carlos Lima Lacerda, Heloisa Ramos Grinsztejn, Beatriz Castilho, Euclides Ayres The HIV-Brazil Cohort Study: Design, Methods and Participant Characteristics |
title | The HIV-Brazil Cohort Study: Design, Methods and Participant Characteristics |
title_full | The HIV-Brazil Cohort Study: Design, Methods and Participant Characteristics |
title_fullStr | The HIV-Brazil Cohort Study: Design, Methods and Participant Characteristics |
title_full_unstemmed | The HIV-Brazil Cohort Study: Design, Methods and Participant Characteristics |
title_short | The HIV-Brazil Cohort Study: Design, Methods and Participant Characteristics |
title_sort | hiv-brazil cohort study: design, methods and participant characteristics |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006775/ https://www.ncbi.nlm.nih.gov/pubmed/24789106 http://dx.doi.org/10.1371/journal.pone.0095673 |
work_keys_str_mv | AT grangeiroalexandre thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT escudermariamercedes thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT cassanotealexjonesflores thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT souzarosaalencar thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT kalichmanarturo thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT velosovaldilea thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT ikedamarialeticiarodrigues thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT barcellosnemoratregnago thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT britescarlos thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT tupinanbasunai thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT lucenanoaldoo thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT dasilvacarloslima thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT lacerdaheloisaramos thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT grinsztejnbeatriz thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT castilhoeuclidesayres thehivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT grangeiroalexandre hivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT escudermariamercedes hivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT cassanotealexjonesflores hivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT souzarosaalencar hivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT kalichmanarturo hivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT velosovaldilea hivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT ikedamarialeticiarodrigues hivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT barcellosnemoratregnago hivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT britescarlos hivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT tupinanbasunai hivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT lucenanoaldoo hivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT dasilvacarloslima hivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT lacerdaheloisaramos hivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT grinsztejnbeatriz hivbrazilcohortstudydesignmethodsandparticipantcharacteristics AT castilhoeuclidesayres hivbrazilcohortstudydesignmethodsandparticipantcharacteristics |